Table 3.
Age-adjusted IRs and IRRs of AML, ALL/L, and AL of ambiguous lineage according to subtype and race/ethnicity, SEER-17, 2001 to 2007
| NHWs |
HWs |
Blacks |
APIs |
IRR |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HWs:NHWs |
Blacks:NHWs |
APIs:NHWs |
||||||||||||
| No. | IR | No. | IR | No. | IR | No. | IR | IRR | 95% CI | IRR | 95% CI | IRR | 95% CI | |
| AML* | 14 177 | 39.9 | 2 216 | 32.3 | 1 492 | 32.0 | 1 439 | 32.3 | 0.81 | 0.77-0.85 | 0.80 | 0.76-0.85 | 0.81 | 0.76-0.85 |
| Subtype | ||||||||||||||
| Group 1 | 11 580 | 32.4 | 1 683 | 25.6 | 1 210 | 26.4 | 1 150 | 26.0 | 0.79 | 0.75-0.84 | 0.82 | 0.77-0.87 | 0.80 | 0.75-0.85 |
| AML, NOS; [M-9861] | 6 355 | 17.6 | 821 | 13.6 | 719 | 16.1 | 583 | 13.5 | 0.77 | 0.71-0.84 | 0.91 | 0.84-0.99 | 0.77 | 0.70-0.84 |
| AML with minimal differentiation; (FAB M0) [M-9872] | 552 | 1.6 | 85 | 1.2 | 67 | 1.5 | 59 | 1.3 | 0.77 | 0.59-0.99 | 0.93 | 0.71-1.21 | 0.85 | 0.63-1.11 |
| AML without maturation; (FAB M1) [M-9873] | 764 | 2.2 | 145 | 2.1 | 62 | 1.3 | 102 | 2.2 | 0.97 | 0.79-1.18 | 0.59 | 0.44-0.77 | 1.03 | 0.83-1.27 |
| AML with maturation; (FAB M2) [M-9874] | 910 | 2.6 | 142 | 2.1 | 80 | 1.8 | 113 | 2.5 | 0.81 | 0.66-0.98 | 0.69 | 0.54-0.88 | 0.97 | 0.79-1.18 |
| Acute myelomonocytic leukemia; (FAB M4) [M-9867] | 1 282 | 3.6 | 223 | 3.2 | 128 | 2.8 | 122 | 2.7 | 0.87 | 0.74-1.02 | 0.77 | 0.63-0.93 | 0.75 | 0.62-0.91 |
| Acute monoblastic and monocytic leukemia; (FAB M5) [M-9891] | 1 106 | 3.2 | 167 | 2.3 | 84 | 1.6 | 99 | 2.2 | 0.72 | 0.60-0.87 | 0.52 | 0.41-0.65 | 0.69 | 0.55-0.85 |
| Acute erythroid leukemia; (FAB M6) [M-9840] | 266 | 0.7 | 28 | 0.4 | 17 | 0.4 | 29 | 0.7 | 0.53 | 0.33-0.80 | 0.48 | 0.27-0.79 | 0.92 | 0.60-1.36 |
| Acute megakaryoblastic leukemia; (FAB M7) [M-9910] | 117 | 0.4 | 40 | 0.4 | 25 | 0.4 | 22 | 0.5 | 1.00 | 0.64-1.54 | 1.18 | 0.72-1.86 | 1.28 | 0.77-2.04 |
| Acute basophilic leukemia; [M-9870] | 4 | ∼ | 0 | ∼ | 0 | ∼ | 1 | ∼ | ∼ | ∼ | ∼ | |||
| Acute panmyelosis with myelofibrosis; [M-9931] | 104 | 0.3 | 8 | ∼ | 11 | 0.3 | 10 | 0.2 | ∼ | 0.86 | 0.41-1.62 | 0.71 | 0.33-1.38 | |
| Myeloid sarcoma; [M-9930] | 120 | 0.3 | 24 | 0.3 | 17 | 0.4 | 10 | 0.2 | 0.83 | 0.49-1.35 | 1.07 | 0.59-1.80 | 0.61 | 0.28-1.16 |
| Group 2 | 1 319 | 4.0 | 410 | 4.5 | 178 | 3.2 | 165 | 3.4 | 1.13 | 1.00-1.27 | 0.81 | 0.69-0.95 | 0.85 | 0.72-1.00 |
| AML with t(8;21); (FAB M2, t(8;21)) [M-9896] | 215 | 0.6 | 38 | 0.4 | 24 | 0.4 | 34 | 0.7 | 0.67 | 0.44-0.98 | 0.70 | 0.44-1.08 | 1.12 | 0.76-1.62 |
| AML with inv(16) or t(16;16); (FAB M4Eo) [M-9871] | 136 | 0.4 | 41 | 0.5 | 8 | ∼ | 15 | 0.3 | 1.11 | 0.74-1.63 | ∼ | 0.71 | 0.38-1.22 | |
| APL with t(15;17); (FAB M3) [M-9866] | 871 | 2.6 | 316 | 3.3 | 140 | 2.5 | 101 | 2.0 | 1.28 | 1.11-1.46 | 0.95 | 0.79-1.14 | 0.77 | 0.61-0.94 |
| AML, 11q23 abnormalities; [M-9897] | 97 | 0.3 | 15 | 0.2 | 6 | ∼ | 15 | 0.4 | 0.84 | 0.42-1.51 | ∼ | 1.24 | 0.66-2.15 | |
| Group 3 | 1 278 | 3.5 | 123 | 2.1 | 104 | 2.4 | 124 | 2.9 | 0.60 | 0.49-0.73 | 0.67 | 0.54-0.82 | 0.81 | 0.67-0.98 |
| AML with myelodysplasia-related changes; [M-9895] | 941 | 2.6 | 84 | 1.5 | 62 | 1.5 | 96 | 2.3 | 0.58 | 0.45-0.73 | 0.59 | 0.44-0.76 | 0.87 | 0.70-1.08 |
| Therapy-related myeloid neoplasms; [M-9920, 9987] | 337 | 1.0 | 39 | 0.6 | 42 | 0.8 | 28 | 0.6 | 0.67 | 0.45-0.95 | 0.89 | 0.62-1.24 | 0.65 | 0.42-0.96 |
| ALL/L* | 4 761 | 16.6 | 2 907 | 24.9 | 644 | 10.2 | 715 | 14.8 | 1.50 | 1.43-1.58 | 0.61 | 0.56-0.67 | 0.89 | 0.82-0.96 |
| Subtype | ||||||||||||||
| B-cell lymphoblastic leukemia/lymphoma; [M-9727(B), 9728, 9835(B), 9836] | 3 133 | 11.0 | 2 094 | 18.1 | 368 | 5.8 | 510 | 10.6 | 1.64 | 1.55-1.74 | 0.52 | 0.47-0.59 | 0.96 | 0.87-1.06 |
| T-cell lymphoblastic leukemia/lymphoma; [M-9727(T), 9729, 9835(T), 9837] | 797 | 2.8 | 313 | 2.6 | 160 | 2.5 | 109 | 2.2 | 0.94 | 0.82-1.08 | 0.90 | 0.75-1.07 | 0.79 | 0.64-0.97 |
| Lymphoblastic leukemia/lymphoma, unknown lineage; [M-9727(U), 9835(U)] | 831 | 2.8 | 500 | 4.2 | 116 | 1.9 | 96 | 2.0 | 1.49 | 1.32-1.69 | 0.68 | 0.55-0.84 | 0.71 | 0.57-0.88 |
| AL ambiguous lineage* | 698 | 1.9 | 126 | 1.9 | 104 | 2.3 | 59 | 1.4 | 0.97 | 0.78-1.20 | 1.20 | 0.96-1.48 | 0.73 | 0.55-0.95 |
| Subtype | ||||||||||||||
| Acute undifferentiated leukemia; [M-9801] | 591 | 1.6 | 91 | 1.5 | 88 | 2.0 | 45 | 1.1 | 0.90 | 0.70-1.15 | 1.24 | 0.97-1.56 | 0.68 | 0.49-0.92 |
| Acute biphenotypic leukemia; [M-9805] | 107 | 0.3 | 35 | 0.4 | 16 | 0.3 | 14 | 0.3 | 1.30 | 0.82-2.00 | 0.99 | 0.53-1.71 | 0.97 | 0.51-1.70 |
All incidence rates are age-adjusted to the 2000 US standard population and expressed per 1 000 000 person-years. IRRs are based on unrounded rates.
NHWs indicates non-Hispanic whites; HWs, Hispanic whites; APIs, Asians/Pacific Islanders; FAB, French–American–British classification; (B), B-cell immunophenotype; (T), T-cell immunophenotype; (U), immunophenotype not specified; and ∼, IRs not calculated for fewer than 10 cases.
*
Includes all ICD-O-3 morphology codes specified within the respective subtype categories. ICD-O-3 codes are specified within brackets.